Clinical trials: Polypoidal Choroidal Vasculopathy
Wet Macular Degeneration
Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy
The purpose of this study is to evaluate the effects and safety of ranibizumab therapy combined with TA versus ranibizumab monotherapy in patients with polypoidal choroidal vasculopathy (PCV).
- Trial name
- RANTA (NCT02806752)
- Testing
- Triamcinolone Acetonide, Ranibizumab
- Where
- 7 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Aier School of Ophthalmology, Central South University
Neovascular Polypoidal Choroidal Vasculopathy
Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)
The purpose of this study is to evaluate the safety and efficacy of intravitreal aflibercept injection (IAI) in patients with neovascular polypoidal choroidal vasculopathy.
- Trial name
- RIVAL (NCT02092532)
- Testing
- Rescue Intravitreal Aflibercept Injection, Rescue Therapy with PDT, Laser or Intravitreal Steroids
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Polypoidal Choroidal Vasculopathy
Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
1. Primary objectives a. To evaluate the Effects of intravitreal Bevacizumab on polypoidal choroidal vasculopathy(PCV) 2. Secondary objectives 1. To assess the changes in visual acuity 2.
- Trial name
- NCT00383812
- Testing
- Intravitreal Bevacizumab
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Asan Medical Center
Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)
A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)
The goal of this clinical trial is to investigate the efficacy, durability, and safety of aflibercept 8 mg in treating Polypoidal Choroidal Vasculopathy (PCV) in Chinese naive patients.
- Trial name
- NCT07365371
- Testing
- Aflibercept Intravitreous Injection
- Where
- 20 sites in China
- Volunteers
- 174 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Polypoidal Choroidal Vasculopathy
Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
This Phase I/II study will investigate the safety and tolerability of intravitreally administered 0.5mg and 1.0 or 2.0mg Ranibizumab in three monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and…
- Trial name
- NCT01469156
- Testing
- ranibizumab 0.5 or 2.0 mg/0.05 cc
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Neovascular Macular Degeneration
Aflibercept in Polypoidal Choroidal Vasculopathy
To collect data reflecting the efficacy and safety of aflibercept with and without photodynamic therapy in subjects diagnosed with the polypoidal choroidal vasculopathy subtype of wet age-related macular degeneration
- Trial name
- PLANET (NCT02120950)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321), Visudyne
- Where
- 62 sites in Australia, Germany and 6 more
- Volunteers
- 333 people
- Sponsor
- Bayer
Pigment Epithelial Detachment
iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
LT1009-Oph-002 is a Phase 1b study designed to evaluate the safety and potential efficacy of iSONEP following one, two or three injections of iSONEP, as needed, for the treatment of Pigment Epithelial Detachment (PED) secondary…
- Trial name
- PED (NCT01334255)
- Testing
- iSONEP (sonepcizumab/LT1009)
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Lpath, Inc.
Neovascular Age-Related Macular Degeneration
Intense Treatment Regimen With Intravitreal Aflibercept Injection
This study will evaluate the safety and efficacy of intense dosing for a limited period in patients who demonstrate refractory disease on monthly IAI. Patients will be followed for 52 weeks
- Trial name
- I-TRAP (NCT03594461)
- Testing
- Aflibercept Injection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Polypoidal Choroidal Vasculopathy
Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
This Phase I/II safety study is designed to investigate the safety and efficacy of ranibizumab (Lucentis) in the treatment of polypoidal choroidal vasculopathy (PCV), a potentially blinding eye disease that involves the growth of…
- Trial name
- NCT00837330
- Testing
- ranibizumab 0.5 or 0.3 mg/0.05 cc
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Polypoidal Choroidal Vasculopathy
Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy
The purpose of this study is to compare the efficacy and safety of intravitreal Aflibercept monotherapy with the efficacy and safety of combined treatment with Aflibercept plus standard photodynamic therapy (PDT) with Verteporfin…
- Trial name
- ATLANTIC (NCT02495181)
- Testing
- Intravitreal Aflibercept
- Where
- 13 sites in Portugal, Spain
- Volunteers
- 50 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Polypoidal Choroidal Vasculopathy
Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy
This is a prospective, comparative control analysis. The investigators want to evaluate the aqueous humor levels of vascular endothelial growth factor in polypoidal choroidal vasculopathy and the effect of photodynamic therapy…
- Trial name
- NCT01360151
- Testing
- ranibizumab(Lucentis), verteporfin(Visudyne)
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Seoul St. Mary's Hospital
Polypoidal Choroidal Vasculopathy
Initial Versus Delayed PDT Combination With Conbercept in PCV
To compare the initial versus delayed verteporfin photodynamic therapy (PDT) in combination with conbercept in patients with symptomatic polypoidal choroidal vasculopathy (PCV).
- Trial name
- NCT02821520
- Testing
- conbercept, Initial PDT, Delayed PDT
- Where
- 3 sites in China
- Volunteers
- 80 people
- Sponsor
- The Eye Hospital of Wenzhou Medical University
Polypoidal Choroidal Vasculopathy
Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs
To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.
- Trial name
- NCT01271426
- Where
- Japan
- Volunteers
- 74 people
- Sponsor
- Nihon University
Polypoidal Choroidal Vasculopathy
Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)
This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.
- Trial name
- PEARL (NCT00424710)
- Testing
- ranibizumab intravitreal injection
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Hawaii Pacific Health
Age-Related Macular Degeneration
Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy
This study is to investigate whether there is an association of the LOC387715/HTRA1 and vascular endothelial growth factor polymorphism with response to treatment with intravitreal ranibizumab injections for patients with…
- Trial name
- NCT01233128
- Where
- South Korea
- Volunteers
- 121 people
- Sponsor
- Kyungpook National University Hospital
PCV, Polypoidal Choroidal Vasculopathy
Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)
This is a 24-month study of ranibizumab (2.0 mg and 1.0 mg) in subjects with polypoidal choroidal vasculopathy as diagnosed by fluorescein/indocyanine green (FA/ICG) angiography.
- Trial name
- PEARL2 (NCT01884597)
- Testing
- high-dose ranibizumab, ranibizumab
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Hawaii Pacific Health
Polypoidal Choroidal Vasculopathy
Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment
In this study, we aim to evaluate the efficacy and safety of an individualized dosing schedule comprising Aflibercept and RF-PDT in patients with polypoidal choroidal vasculopathy (PCV).
- Trial name
- NCT03941587
- Testing
- Aflibercept + reduced fluence photodynamic therapy (RF-PDT)
- Where
- 2 sites in Singapore
- Volunteers
- 60 people
- Sponsor
- Singapore National Eye Centre
Uveitis, Diabetic Retinopathy
Biomarkers of Common Eye Diseases
To identify biomarkers of common eye diseases based on single-cell sequencing technologies using PBMC samples. These diseases include uveitis, diabetic retinopathy, age-related macular degeneration and polypoid choroidal…
- Conditions
- Uveitis, Diabetic Retinopathy, Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
- Trial name
- NCT04101604
- Testing
- Collection of blood samples
- Where
- China
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Polypoidal Choroidal Vasculopathy
Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy
The purpose of this study is to determine whether double-dose Ranibizumab are effective to regress the polyps and benefit to the visual outcome in the polypoidal choroidal vasculopathy (PCV).
- Trial name
- NCT02769169
- Testing
- Lucentis® (Raibizumab) double-dose, Lucentis® (Raibizumab) regular-dose
- Where
- 4 sites in China
- Volunteers
- 5 people
- Sponsor
- Sun Yat-sen University
Polypoidal Choroidal Vasculopathy
Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation
To evaluate the efficacy and safety of intravitreal aflibercept injection in the treatment of PCV
- Trial name
- EPIC (NCT01871376)
- Testing
- Intravitreal aflibercept injection 2.0mg
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Gregg T. Kokame, MD